CymaBay meets primary, key secondary endpoints in PhIII liver trial

Paul Schloesser

Associate Editor

CymaBay Therapeutics’ lead candidate met the primary endpoint and key secondary endpoints in a Phase III trial for a liver disease, setting the stage for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CymaBay meets primary, key secondary endpoints in PhIII liver trial

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Exclusive: Drugmakers plan Trump meeting next week amid Washington health shakeups

Healthcare shakeup hits Washington, with cuts at CDC, NIH and other agencies

Kojin Therapeutics shuts down, citing lack of investor interest and complex science

BioNTech vets raise $90M Series A for bispecific I&I startup

How Bain’s $3.3B deal for centuries-old Tanabe Pharma came to fruition

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

CymaBay meets pri­ma­ry, key sec­ondary end­points in PhI­II liv­er tri­al

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

CymaBay meets primary, key secondary endpoints in PhIII liver trial